DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20181744

Translational pharmacology: role and its impact

Sumit Kumar, Bhagya M. Sattigeri

Abstract


Translational Pharmacology is a newly evolved branch as an extension of clinical pharmacology. Translational Pharmacology aims to move the results of the molecular pharmacological research to the patient level, which is focussed on developing the new drug that correlates with the patient needs. The basic objective is to study the changing trends from experimental to clinical pharmacology. It also helps to gather data from the preclinical studies, so as to have accurate and effective dosing in the critical clinical trials. Thus, we can conclude that Translational Pharmacology tries to bridge the gap between the basic molecular research studies in pharmacology to the clinical trials. This also reduces the time and economic burden on research. Thus, it helps in translating the knowledge from the basic animal studies to the bedside patient studies.


Keywords


Clinical trial, Translational, Molecular pharmacology

Full Text:

PDF

References


Kshirsagar NA. History of clinical pharmacology in India: A brief account. In: Patil PN, Gulati OD, Balaraman R, editors. Chapter in the book on ‘Topics in the History of Pharmacology’. Ahmadabad, India: Publisher RK Goyal;2005:148-69.

Dollery CT. Clinical pharmacology-The first 75 years and a view of the future. Br J Clin Pharmacol. 2006;61:650-65.

Hay JW. Using pharmacoeconomics to value pharmacotherapy. Clinical Pharmacology and Therapeutics. 2008;84(2):197-200.

Pizzi LT, Singh VP. Pharmacoeconomics is coming of age. Clinical Pharmacology Therapeutics. 2008;84(2):188-90.

Lesko LJ. Paving the critical path: how can clinical pharmacology help achieve the vision? Clinical Pharmacology and Therapeutics. 2007;81(2):170-7.

Woodcock J. The prospects for “personalized medicine” in drug development and drug therapy. Clinical Pharmacol Therapeutics. 2007;81(2):164-9.

Cortese DA. A vision of individualized medicine in the context of global health. Clinical Pharmacol Therapeutics. 2007;82(5):491-3.

Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit‐for‐purpose development and regulatory evaluation of new drugs. Clinical Pharmacol Therapeutics. 2007;81(1):104-7.

Waldman SA, Terzic A. Pharmacoeconomics in the era of individualized medicine. Clinical Pharmacol Therapeutics. 2008;84(2):179-82.

Anger GJ, Piquette-Miller M. Translational pharmacology: harnessing increased specialization of research within the basic biological sciences. Clin Pharmacol Ther. 2008;83(6):797-801.

Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genetics in Medicine. 2007;9(10):665-74.

Ledford H. Translational research: the full cycle. Nature News. 2008;453(7197):843-5.

Disis ML, Slattery JT. The road we must take: multidisciplinary team science. Science translational medicine. 2010;2(22):22cm9.

Cohrs RJ, Martin T, Ghahramani P, Bidaut L, Higgins PJ, Shahzad A. Translational medicine definition by the European Society for Translational Medicine. 2015:86-8.

Woolf SH. The meaning of translational research and why it matters. JAMA. 2008;299(2):211-3.

Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012;483(7391):531.

Curry S, McCarthy D, DeCory H, Marler M, Gabrielsson J. Phase I: the first opportunity for extrapolation from animal data to human exposure. Principles and practice of pharmaceutical medicine. 2nd ed. West Sussex: Wiley. 2007:79-100.

Ludwig Institute for Cancer Research. New computational tool for cancer treatment. Science Daily. 2010.

University of Surrey. In Silico cell for TB Drug Discovery. ScienceDaily. 2017. Retrieved on February 12, 2010.

Hurko O. The uses of biomarkers in drug development. Annals of the New York Academy of Sciences. 2009;1180(1):1-0.

US food and drug administration. FDA guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005.

Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clinical Pharmacol. 2008;48(5):632-49.

Rosenblum D, Alving B. The role of the clinical and translational science awards program in improving the quality and efficiency of clinical research. CHEST J. 2011;140(3):764-7.